What is the Return on Assets (ROA) of Immutep this year?
The Return on Assets (ROA) of Immutep is -0.27 undefined this year.
Immutep ROA 2024
Immutep ROA
-0.27
Ticker
IMM.AX
ISIN
AU000000IMM6
WKN
A2H81H
In 2024, Immutep's return on assets (ROA) was -0.27, a -14.18% increase from the -0.32 ROA in the previous year.
Immutep Aktienanalyse
What does Immutep do?
Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company was founded in 2001 and is headquartered in Sydney, Australia. The history of Immutep began with the discovery of a new type of T-cell receptor, known as lymphocyte activation gene-3 (LAG-3) receptors, which are involved in the activation of T-cells. The company used this knowledge to develop a platform of immunotherapeutics based on the stimulation of LAG-3 receptors, with the goal of enhancing the body's immune response against cancer and autoimmune diseases. Immutep's business model is based on the development and commercialization of immunotherapeutics that target LAG-3 receptors. The company focuses on the clinical development of therapeutics targeting various stages of cancer, such as lung cancer, prostate cancer, and breast cancer. Additionally, the company is also developing therapeutics for the treatment of autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and Crohn's disease. Immutep is divided into various divisions to coordinate its activities in the areas of research and clinical development. These divisions include clinical development, research and development, and the production of immunotherapeutics. In the clinical development division, Immutep focuses on demonstrating the safety and efficacy of its immunotherapeutics in the treatment of cancer and autoimmune diseases. The company conducts clinical trials to evaluate the effectiveness of its therapeutics and obtain regulatory approval. Immutep's research and development department focuses on developing innovative immunotherapeutics based on LAG-3 receptors. The company has developed several patented technologies that enhance the effectiveness of the therapeutics and increase the body's tolerance to them. Immutep also operates a production division specializing in the manufacturing of immunotherapeutics. The company has production facilities in Europe and Asia, allowing it to distribute its therapeutics worldwide. The company offers a range of immunotherapeutics based on the stimulation of LAG-3 receptors. These therapeutics have been specifically developed for the treatment of cancer and autoimmune diseases and have the potential to enhance the body's immune response against these conditions. Immutep's products include IMP321, an immunotherapeutic specifically developed for the treatment of prostate cancer, and IMP701, an immunotherapeutic specifically developed for the treatment of lung cancer. Additionally, the company has several new therapeutics in clinical development, including IMP761 for the treatment of systemic lupus erythematosus and IMP731 for the treatment of Crohn's disease. Immutep is a leading company in the development of immunotherapeutics based on LAG-3 receptors. The company has a strong pipeline of therapeutics in clinical development and is well-positioned to benefit from the growing demand for immunotherapeutics for the treatment of cancer and autoimmune diseases. With its patented technologies and expertise in clinical development of immunotherapeutics, Immutep is well-equipped to grow and solidify its position as a leading company in this field. Immutep ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Immutep's Return on Assets (ROA)
Immutep's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Immutep's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Immutep's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Immutep’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Immutep stock
What was the ROA of Immutep compared to the previous year?
The ROA of Immutep has increased by -14.18% compared to the previous year.
What consequences do high ROA have for investors of Immutep?
A high ROA is advantageous for investors of Immutep, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Immutep?
A low ROA can be unfavorable for investors of Immutep as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Immutep affect the company?
An increase in ROA of Immutep can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Immutep impact the company?
A reduction in the ROA of Immutep can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Immutep?
Some factors that can influence the ROA of Immutep include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Immutep important for investors?
The ROA of Immutep is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Immutep take to improve ROA?
To improve ROA, Immutep can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Immutep pay?
Over the past 12 months, Immutep paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immutep is expected to pay a dividend of 0 AUD.
What is the dividend yield of Immutep?
The current dividend yield of Immutep is .
When does Immutep pay dividends?
Immutep pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immutep?
Immutep paid dividends every year for the past 0 years.
What is the dividend of Immutep?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immutep located?
Immutep is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immutep kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immutep from 8/26/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.
When did Immutep pay the last dividend?
The last dividend was paid out on 8/26/2024.
What was the dividend of Immutep in the year 2023?
In the year 2023, Immutep distributed 0 AUD as dividends.
In which currency does Immutep pay out the dividend?
The dividends of Immutep are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immutep
Our stock analysis for Immutep Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immutep Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
